Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
about
Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person SyndromeThe lung in ACPA-positive rheumatoid arthritis: an initiating site of injury?Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic RatsUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system.Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.Rituximab for Rheumatoid Arthritis.Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patientsFrom synovial tissue to peripheral blood: myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritisProstaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expressionEctopic lymphoid neogenesis in rheumatic autoimmune diseases.Evaluation of arthroscopy and macroscopic scoring.B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers.Can Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis?V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis.Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease statesRationale of using different biological therapies in rheumatoid arthritis.Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis.B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status.Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm.Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity.Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.Is there a role of synovial biopsy in drug development?Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunityPrevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissueSuppressed diversity of survivin splicing in active rheumatoid arthritis.A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis.CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patientsSafety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical responseNijmegen breakage syndrome and chronic polyarthritis.Garden of therapeutic delights: new targets in rheumatic diseasesB-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.Rituximab for the treatment of rheumatoid arthritis: an update.Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.
P2860
Q21136358-688335CD-C848-48C0-9DDE-031F0F49AA6EQ27023243-4241E5E5-A1B4-4D2A-AE6B-5994F51BCEA7Q27345563-9C09BB62-BA7D-489B-8F7C-2084FB2E66B0Q27691388-7C4A0FE6-CABE-422E-9C5D-9848EC8623F4Q27692640-7F30BE3B-0034-4396-8634-2FA25BEFEE74Q27692641-74C84F93-7129-44BD-B731-29D2FC9BFD09Q28080246-8BC55FFD-45A2-4B8C-AE07-3F6638BC5773Q28290930-A49B27BF-C620-4492-8FDE-B40B8CF02F2CQ28542641-960EDBAA-B299-4F99-887C-D8A123BFEF79Q28743224-DB8993FA-9AE6-453D-AC02-BE0166B25351Q30235935-13D1499B-E6A5-4187-8B3B-C589FC9BADEAQ30488975-6008BF60-E50F-4872-8E25-16CE6A4CBBAFQ33616360-E9144B34-FF5C-449E-8804-F77502A6091FQ33627758-73D9086E-AF3E-43F8-9518-E1901BDCDDD6Q33706440-B220FEFA-CFC5-42BE-8CDF-B8A15EE2285CQ34047769-3E7FDAFF-1A49-49F8-AE91-736EBA979941Q34153073-128A01AA-E33D-4BA8-A1B6-B42FCC759318Q34810094-529AB98C-618A-4225-82A7-D4A6279B9921Q35286950-BFA47AE8-6891-4EBF-A4F0-20F19B53D26AQ35418255-A396456D-8A77-4506-AB23-A0278BDB0231Q35605477-263E4FDE-0BF8-430F-AE61-9D411B791C4CQ35654669-6295E118-9E1F-46B0-A17F-83D570D5AB25Q35835741-B3E51B62-D03A-43D9-BA78-219ACD555F53Q35858046-36C547A0-301A-452C-AA19-DF81217787BCQ35953366-417894ED-D898-4B64-BB77-D5E8E2A71942Q35994130-62A79283-5DF5-4BE8-9713-CC143F0F3931Q36245714-E1C52FBA-A47E-43FE-B271-2CEB116822D0Q36322970-3FAB76D7-D8FE-43DA-9774-68BF78D8EED6Q36433351-F22A0072-8C6F-4AF0-9B86-DF25F7EC0E1EQ37203531-8AED71E8-FE5C-4796-BEE9-D6C24220D539Q37270745-849DCBE6-9538-4AEE-A650-008ACC4E5111Q37282164-139A4E2B-34C5-49A0-9762-12EA83F87EC8Q37326017-F0E4C072-7ED4-4AAC-9F87-F0FCC6D3B233Q37350931-7F070ECD-AE95-455A-9B9B-9CD721A69883Q37350960-F4743240-9CDD-47D5-B2D4-9CF9517BCEBBQ37362224-E8B1B15A-F989-4E08-B4DF-F4864DE8C4C4Q37397656-B9ECD06C-2ECD-4ABE-BA26-27D45F6DFFFEQ37424048-27421393-1556-43B2-8847-D64A718222D0Q37444678-687B43B7-D219-4EE2-9D8D-146875D6F03FQ37552019-3E2BACF7-DCD5-45BC-8EB0-FC20C9ABFBB3
P2860
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Synovial tissue response to ri ...... tion of biomarkers of response
@en
type
label
Synovial tissue response to ri ...... tion of biomarkers of response
@en
prefLabel
Synovial tissue response to ri ...... tion of biomarkers of response
@en
P2093
P2860
P356
P1476
Synovial tissue response to ri ...... tion of biomarkers of response
@en
P2093
P2860
P304
P356
10.1136/ARD.2007.080960
P407
P577
2007-10-26T00:00:00Z